NOVOGEN Ltd. and Genentech entered an agreement to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase pathway. Genentech is a member of the Roche Group. Novogen is an Australian-based company. The lead indication for GDC-0084 is glioblastoma multiforme. GDC-0084 is distinguished from most molecules in the class by its ability to cross...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
